A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients

Antiviral Therapy

Volumn 7, Issue 2, 2002, Pages 123-129

  Van Laethem, Kristel ^a   De Luca, Andrea ^b   Antinori, Andrea ^c   Cingolani, Antonello ^b   Perno, Carlo Federico ^c   Vandamme, Anne Mieke ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b CATHOLIC UNIVERSITY   (Italy)

^c NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA;

ALGORITHM; ARTICLE; DRUG SENSITIVITY; GENETIC RESISTANCE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD; ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; GENETICS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; RETROSPECTIVE STUDY; STATISTICAL MODEL;

ADOLESCENT; ADULT; ALGORITHMS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NELFINAVIR; RETROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0036616384     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. The EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS 2001; 15:309-320.
2. Vandamme A-M, Houyez F, Bànhegyi D, Clotet B, De Schrijver G, De Smet KAL, Hall WW, Harrigan R, Hellmann N, Hertogs K, Holtzer C, Larder B, Pillay D, Race E, Schmit J-C, Schuurman R, Shulse E, Sönnerborg A & Miller V. Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up. Antiviral Therapy 2001; 6:21-40.
3. Hirsch MS, Brun-Vézinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, Loveday C, Mellors JW, Clotet B, Conway B, Demeter LM, Vella S, Jacobsen DM & Richman DD. Antiretroviral drug resistance testing in adult HIV-1 infection. Recommendations of an international AIDS Society-USA panel. Journal of the American Medical Association 2000; 283:2417-2426.
4. Katzenstein TL, Jorgensen LB, Nielsen H, Kirk O, Schuurman R, Nielsen C & Gerstoft J. Lack of obvious interplay between baseline genotype and virological response among protease inhibitor-naïve patients treated with HAART. Antiviral Therapy 1999; 4(Suppl. 1):68.
5. Zolopa AR, Shafer RW, Warford A, Montoya JG, Hsu P, Katzenstein D, Merigan TC & Efron B. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Annals of Internal Medicine 1999; 131:813-821.
6. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montagne N, Boucher CAB, Schapiro JM & Dellamonica P. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. The Lancet 1999; 353:2195-2199.
7. Meynard JL, Vray M, Morand-Jouvert L, Matheron S, Peytavin G, Clavel F, Brun-Vezinet F & Girard PM. Impact of treatment guided by phenotypic or genotypic resistance tests on the response to antiretroviral therapy: a randomized trial (NARVAL, ANRS 088). Antiviral Therapy 2000; 5(Suppl. 3):67.
8. Schinazi RF, Larder B & Mellors JW. Mutations in retroviral genes associated with drug resistance: 2000-2001 update. International Antiviral News 2000; 8:65-91.
9. Shafer RW, Jung DR, Betts BJ, Xi Y & Gonzales MJ. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Research 2000; 28:346-348.
10. Murri R, Ammassari A, Gallicano K, De Luca A, Cingolani A, Jacobson D, Wu AW & Antinori A. Patient-reported nonadherence to HAART is related to protease inhibitor levels. Journal of Acquired Immune Deficiency Syndromes 2000; 24:123-128.
11. Tural C, Ruiz L, Holzer C, Schapiro J, Viciana P, Gonzalez J, Domingo P, Boucher CAB, Rey-Joly C & Clotet B. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002; 16:209-218.
12. De Gruttola V, Dix L, D'Aquila RT, Holder D, Phillips A, Ait-Khaled M, Baxter J, Clevenbergh P, Hammer S, Harrigan R, Katzenstein D, Lanier R, Miller M, Para M, Yerly S, Zolopa A, Murray J, Patick A, Miller V, Castillo S, Pedneault L & Mellors J. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Therapy 2000; 5:41-48.
13. De Luca A, Cingolani A, Trotta MP, Di Giambenedetto S, Bertoli A, Rizzo MG, Liuzzi G, Murri R, Baldini F, Ippolito G, Perno CF & Antinori A. Prediction of virological and immunological outcomes by different interpretation systems for genotypic resistance in a cohort of highly active antiretroviral therapy-failed patients. Antiviral Therapy 2001; 6(Suppl 1):70.